|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ֳ������ |
|
���в�ѧ |
|
��� |
|
ҩ���Ʒ� |
|
�ۺ�Ԥ�� |
| ��������������� | |
|
�߰��� |
|
����ɭ |
| PubMed | |
|
Article by |
|
Article by |
��ֳ��������ν�չ
�߰���, ����ɭ
���пƼ���ѧͬ��ҽѧԺ����ͬ��ҽԺƤ����, �人 430030
��ֳ���������ɵ����������Ⱦ������Դ�������.�˲����ڸ���,�Ի����������кܴ��Ӱ��.�����������Ⱦ��HIV��Ⱦ�����й�ϵ.��ֳ��������ٴ����ֶ���,Ŀǰ������ֳ���������ϻ��������.��Щҩ�����������ֳ������IJ���,���Լ����临���������ڿ�����ֳ������Ĵ���.��ȫ�͵���������������ֳ������Ĵ���Ҳ��һ����Ԥ������.
[2] Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med, 1997,337:1105-1111.
[3] Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes, 2004, 11(Suppl 1):24A-35 A.
[4] Lafferty WE, Downey L, Celum C, et al. Herpes simplex virus type 1 as a cause of genital herpes:impact on surveillance and prevention. J Infect Dis, 2000, 181:1454-1457.
[5] Celum CL. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes, 2004, 11(Suppl 1):36A-45A.
[6] Wald A, Link K. Risk of human immunodefieiency virus infection in herpes simplex virus type 2 seropositive persons:a meta-analysis. J Infect Dis, 2002, 185:45-52.
[7] Mertz K J, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis,1998, 178:1795-1798.
[8] The Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR, 2002,16-17.
[9] Morrow RA, Friedrich D. Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2. Am J Clin Pathol, 2003, 120:839-844.
[10] Patel R, Tyring S, Strand A, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect, 1999, 75:398-402.
[11] Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med, 2004, 350:11-20.
[12] Miller RL, Tomai MA, Harrison CJ, et al. Immunomodulation as a treatment strategy for genital herpes:review of the evidence. Int Immunopharmacol, 2002, 2:443-451.
[13] Spruance SL, Tyring SK, Smith MH, et al. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes:a pilot study. J Infect Dis, 2001,184:196-200.
[14] Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA, 2001, 285:3100-3106.
[15] Stanberry LR, Spruance SL, Cunningham AL,et al. Glycoprotein-Dadjuvant vaccine to prevent genital herpes. N Engl J Med, 2002,347:1652-1661.
[16] Casanova G, Cancela R, Alonzo L,et al. A double-blind study of the efficacy and safety of the ICP10 delta PK vaccine against recurrent genital HSV 2 infections. Cutis, 2002, 70:235-239.